Intravitreal bevacizumab injection in advanced retinopathy of prematurity.

To report the efficacy of intravitreal bevacizumab injection for advanced retinopathy of prematurity (ROP) patients. A retrospective chart review was performed for 19 advanced ROP patients (34 eyes), who had intravitreal bevacizumab injection between January 1, 2007 and July 31, 2009 at Chiang Mai U...

全面介紹

Saved in:
書目詳細資料
Main Authors: Choovuthayakorn J., Ubonrat K.
格式: Article
語言:English
出版: 2014
在線閱讀:http://www.scopus.com/inward/record.url?eid=2-s2.0-84864867490&partnerID=40&md5=ecf484f4db43387b304475ebd69a186c
http://cmuir.cmu.ac.th/handle/6653943832/3919
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
機構: Chiang Mai University
語言: English
id th-cmuir.6653943832-3919
record_format dspace
spelling th-cmuir.6653943832-39192014-08-30T02:35:28Z Intravitreal bevacizumab injection in advanced retinopathy of prematurity. Choovuthayakorn J. Ubonrat K. To report the efficacy of intravitreal bevacizumab injection for advanced retinopathy of prematurity (ROP) patients. A retrospective chart review was performed for 19 advanced ROP patients (34 eyes), who had intravitreal bevacizumab injection between January 1, 2007 and July 31, 2009 at Chiang Mai University Hospital. The baseline characteristics including gestational age, postmenstrual age of first injection, anterior and posterior segment changes, and complications between treatments to 1-year followed-up were analyzed. The patients were divided into 2 groups according to the indications for treatment. Group 1, two patients (4 eyes), received initial intravitreal bevacizumab injection followed by laser photocoagulation due to aggressive posterior disease. Group 2, seventeen patients (30 eyes), received intravitreal bevacizumab injection due to persistence of the vascular activity after laser treatment. There were statistical significant difference between the two groups in terms of a mean gestation age, a mean birth weight, and a mean time for first intravitreal injection (p = 0.002, 0.008, and 0.007 respectively). However, there was no statistical significant difference between the two groups in terms of timing for resolution of vascular activity and retinal vasculogenesis across the laser scar (p = 0.172). One patients with aggressive posterior disease progressed to stage 4A ROP with successful anatomical attachment by pars plana vitrectomy. At 1-year follow-up, no other ocular or systemic side effects were observed. There was no statistical significant difference of a mean spherical equivalent between the two groups (p = 0.280). Intravitreal bevacizumab injection is an effective procedure either as an adjuvant or initial treatment in advanced ROP cases. 2014-08-30T02:35:28Z 2014-08-30T02:35:28Z 2012 Article 1252208 22696855 http://www.scopus.com/inward/record.url?eid=2-s2.0-84864867490&partnerID=40&md5=ecf484f4db43387b304475ebd69a186c http://cmuir.cmu.ac.th/handle/6653943832/3919 English
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
language English
description To report the efficacy of intravitreal bevacizumab injection for advanced retinopathy of prematurity (ROP) patients. A retrospective chart review was performed for 19 advanced ROP patients (34 eyes), who had intravitreal bevacizumab injection between January 1, 2007 and July 31, 2009 at Chiang Mai University Hospital. The baseline characteristics including gestational age, postmenstrual age of first injection, anterior and posterior segment changes, and complications between treatments to 1-year followed-up were analyzed. The patients were divided into 2 groups according to the indications for treatment. Group 1, two patients (4 eyes), received initial intravitreal bevacizumab injection followed by laser photocoagulation due to aggressive posterior disease. Group 2, seventeen patients (30 eyes), received intravitreal bevacizumab injection due to persistence of the vascular activity after laser treatment. There were statistical significant difference between the two groups in terms of a mean gestation age, a mean birth weight, and a mean time for first intravitreal injection (p = 0.002, 0.008, and 0.007 respectively). However, there was no statistical significant difference between the two groups in terms of timing for resolution of vascular activity and retinal vasculogenesis across the laser scar (p = 0.172). One patients with aggressive posterior disease progressed to stage 4A ROP with successful anatomical attachment by pars plana vitrectomy. At 1-year follow-up, no other ocular or systemic side effects were observed. There was no statistical significant difference of a mean spherical equivalent between the two groups (p = 0.280). Intravitreal bevacizumab injection is an effective procedure either as an adjuvant or initial treatment in advanced ROP cases.
format Article
author Choovuthayakorn J.
Ubonrat K.
spellingShingle Choovuthayakorn J.
Ubonrat K.
Intravitreal bevacizumab injection in advanced retinopathy of prematurity.
author_facet Choovuthayakorn J.
Ubonrat K.
author_sort Choovuthayakorn J.
title Intravitreal bevacizumab injection in advanced retinopathy of prematurity.
title_short Intravitreal bevacizumab injection in advanced retinopathy of prematurity.
title_full Intravitreal bevacizumab injection in advanced retinopathy of prematurity.
title_fullStr Intravitreal bevacizumab injection in advanced retinopathy of prematurity.
title_full_unstemmed Intravitreal bevacizumab injection in advanced retinopathy of prematurity.
title_sort intravitreal bevacizumab injection in advanced retinopathy of prematurity.
publishDate 2014
url http://www.scopus.com/inward/record.url?eid=2-s2.0-84864867490&partnerID=40&md5=ecf484f4db43387b304475ebd69a186c
http://cmuir.cmu.ac.th/handle/6653943832/3919
_version_ 1681420139451383808